In PLOS this week: COLEC10 linked to craniofacial development, transcripts and peptides of spider venom, and more.
The WUSTL-developed method detects a bile acid that is found at increased levels in Niemann-Pick patients, and is ready for pilot testing, its developers said.
At next week's workshop on the validation of LC/MS-based protein and peptide tests, the FDA hopes to determine what it needs to demand from test developers.
Agilent will provide technology and training for the jointly-run lab, expanding on a 2011 deal to open a microarray technology center at Monash University Malaysia.
Scientists from the Okinawa Institute of Science and Technology and Kyoto University have found 14 metabolites whose levels differ in older individuals' blood.
The announcement comes as the agency is preparing to regulate laboratory developed tests as medical devices, including those based on mass spectrometry.
Advion is opening a new services facility in Indianapolis, and Eli Lilly will transition its drug discovery bioanalytical capability to the firm.
Bio-analytical segment revenues dipped 8 percent to $496 million, with life sciences down 5 percent to $234 million.
Pacific Biosciences is hosting a competition in which researchers are vying to win free sequencing for an organism with the most interesting genome.
An opinion piece appearing in Newsday likens familial DNA searches to stop-and-frisk policies.
The San people of Africa have drawn up a code of conduct for researchers, according to the Conversation.
In Nature this week: genotypes linked to hip osteoarthritis, and more.